Immunome earnings and shelf registration put recent stock move in focus

Immunome (IMNM) has drawn fresh investor attention after reporting second quarter and six month results that showed a wider net loss, alongside a new shelf registration to potentially issue additional common shares.

Those results and the new shelf registration have landed against a backdrop of strong momentum in Immunome’s stock, with a 30-day share price return of 22.76% and a 1-year total shareholder return of 173.45%. This suggests investors are weighing higher growth expectations against increased loss and dilution risk.

If Immunome’s move has you looking at other oncology and biotech ideas linked to advanced technology, it could be worth scanning for specialised healthcare opportunities using our healthcare AI stocks screener, starting with 40 healthcare AI stocks.

After a 1 year total return of 173.45% and a recent lift in Immunome’s share price, alongside widening losses and a fresh shelf registration, the next step is clear: How much upside, if any, is still ahead on valuation?

Preferred Price-to-Book Multiple of 5.9x for Immunome: Is it justified?

Based on current data, Immunome is trading on a P/B of 5.9x compared with an average of 4.4x for its direct peers and 2.4x for the broader US biotechs industry. At a last close of $27.40, that puts the stock at a meaningfully richer valuation than many comparable biotechs.

The P/B ratio compares a company’s market value to its book value. For early stage biotech companies with limited revenue and ongoing losses, investors often look at P/B as a rough gauge of how the market prices the underlying assets, pipeline and balance sheet relative to accounting equity.

In Immunome’s case, a 5.9x P/B alongside no meaningful revenue and a reported net loss of $254.323m suggests investors are paying a premium to book value that reflects expectations around its oncology pipeline rather than current earnings power. Relative to both its specific peer group at 4.4x and the wider US biotechs average at 2.4x, the current multiple implies materially higher embedded expectations for future progress.

Result: Price-to-book of 5.9x (OVERVALUED)

However, Immunome’s widening net loss of $254.323m and the new shelf registration that could lead to further dilution both sit uncomfortably against the current premium P/B.

Another view on Immunome’s valuation

The P/B comparison paints Immunome as expensive, yet the SWS DCF model points in the opposite direction. At $27.40, the stock is described as trading 76.3% below an estimated fair value of $115.62. One model flags rich expectations; the other suggests a wide discount. Which signal do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Immunome for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals around Immunome’s valuation and future potential, it makes sense to move quickly and check the underlying data yourself. To see both sides of the story and weigh the upside against the concerns, review the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Immunome?

Do not stop with Immunome. Use the Simply Wall Street Screener to quickly spot fresh stock ideas that fit your style before other investors move first.

• Target value opportunities by checking companies that look mispriced on quality and fundamentals through the 53 high quality undervalued stocks.
• Strengthen your income stream by focusing on businesses with higher yields using the 10 dividend fortresses.
• Dial down risk by focusing on companies with stronger balance sheets and fundamentals using the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.